Synlogic

190 articles about Synlogic

• Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

  12/7/2023

  Synlogic, Inc. announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU) has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.

• Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

  9/29/2023

  Synlogic, Inc. announced the pricing of an underwritten public offering of 7,394,363 shares of common stock and accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock.

• Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

  9/19/2023

  Synlogic, Inc. announced that CEO Aoife Brennan, M.B. Ch.B., has been honored as a PharmaVoice 100 winner, a list recognizing the most inspiring people in the life sciences industry.

• Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)

  7/11/2023

  Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.

• Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

  7/11/2023

  Synlogic, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to labafenogene marselecobac for the treatment of phenylketonuria.

• Synlogic Announces International Nonproprietary Name Selection for SYNB1934

  6/28/2023

  Synlogic, Inc. today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected "labafenogene marselecobac" for the nonproprietary name of the company’s investigational drug for phenylketonuria (PKU), previously known as SYNB1934.

• Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

  6/27/2023

  Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023.

• Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

  6/8/2023

  Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST.

• Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

  6/5/2023

  Synlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria.

• Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

  5/9/2023

  Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, announced that the U.S. Food and Drug Administration has granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria.

• Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

  3/29/2023

  Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update.

• Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

  1/19/2023

  Synlogic, Inc. today announced that SYNB1934 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of phenylketonuria (PKU).

• Synlogic Provides Corporate Update and Outlook for 2023

  1/5/2023

  Synlogic, Inc., a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, summarized accomplishments for 2022 and outlined anticipated key milestones for 2023.

• Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

  11/30/2022

  Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB1353 has achieved proof of mechanism and positive results in a Phase 1 study in healthy volunteers treated with multiple ascending doses of SYNB1353.

• 

  New Approaches Emerge for a Prevalent Nemesis: Gout

  10/12/2022

  Incidence of gout - the most common inflammatory arthritis in the world - are on the rise. Arthrosi Therapeutics, Synlogic, Atom Bioscience and Ginkgo Bioworks are on the case with novel new approaches.
• 

  Synlogic’s CSO Outlines Risks and Opportunities in Emerging Synthetic Biotics Space

  10/5/2022

  Synlogic, Senti Biosciences and Novome are pioneering the field of synthetic biotics, which is so new there are only a handful of scientific articles using either that term or ‘engineered living therapeutics.
• 

  FDA Review: Incyte, Pfizer, Iovance and More

  8/26/2022

  The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.

• Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

  8/23/2022

  Synlogic, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SYNB1353 for the potential treatment of homocystinuria (HCU).

• Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

  8/11/2022

  Synlogic, Inc. today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming.

• Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/11/2022

  Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its pipeline programs.